DelveInsight’s ‘Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast-2030’ report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inducible Urticaria (CIndU) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Chronic Inducible Urticaria market report provides analysis regarding current treatment practices, emerging drugs like AK002, potential therapies, market share of the individual therapies, and historical, current and forecasted Chronic Inducible Urticaria market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Chronic Inducible Urticaria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Overview
Urticaria, also known as hives, is a common, mast cell‐driven, itchy condition which is characterized by red/pink, swollen whealing of the skin. Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema or both, as a response to specific triggers.
CIndU includes symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria and aquagenic urticaria. Two or more different subtypes of urticaria may coexist in any given patient.
Chronic Inducible Urticaria Treatment
Management of CIndU typically involves threshold testing and consecutive avoidance of relevant triggers. Where this is not possible or feasible, symptomatic treatment follows a stepwise approach, starting with a standard dose of non-sedating H1-antihistamines. Dosing can be increased up to four-fold, which represents an off-label use because patients with CIndU can benefit from up dosing.
This chapter covers the details of conventional and current medical therapies available for the treatment of CIndU. It also provides the country-wise CIndU treatment guidelines across the United States, Europe and Japan.
DelveInsight’s Chronic Inducible Urticaria market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Chronic Inducible Urticaria treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Chronic Inducible Urticaria Epidemiology
The Chronic Inducible Urticaria epidemiology chapters provide insights about historical and current Chronic Inducible Urticaria patient pool and forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. CIndU epidemiology is segmented by the diagnosed prevalent cases of CU, diagnosed prevalent cases of CIndU, prevalence of chronic inducible urticaria by types. Besides, the report includes a thorough analysis of all segments.
It has been observed that about 50% cases of CIndU are symptomatic dermographism and 20% each are cold urticaria and cholinergic urticaria; the other 10% are the other forms of CIndU.
According to DelveInsight’s, the total Chronic Inducible Urticaria prevalent population in seven major markets was 652,542 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, total prevalent cases for Chronic Inducible Urticaria were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.
This segment encloses the detailed analysis of the drugs in the Chronic Inducible Urticaria pipeline. It also helps to understand the CIndU clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
The therapeutic goal of CIndU management primarily focusses on achieving complete symptom control, by trigger avoidance, desensitization, blocking the effects of mast cell mediators (non-sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for the treatment of CIndU apart from symptomatic management.
The pipeline scenario does not represent a particularly close picture with only one major player making major inroads in the largely untapped market to date. AK002 (Antolimab) being developed by Allakos Pharma is the only candidate with the potential to enter the arena during the forecast period and has completed Phase II trials.
The market size of Chronic Inducible Urticaria(CIndU) is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Chronic Inducible Urticaria market size. Among EU5 countries, Germany had the largest market size, with USD 172 million in 2017, while Spain had the smallest Chronic Inducible Urticaria market size with USD 104.5 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the Chronic Inducible Urticaria market or expected to get launched in the market during the study period 2017–2030. The analysis covers Chronic Inducible Urticaria market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Chronic Inducible Urticaria market is anticipated to experience a positive shift in the coming years owing to the expected launch of AK002 (Allakos) during the forecasted period 2020-2030.
Chronic Inducible Urticaria: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning chronic inducible urticaria.
To keep up with current market trends, we take KOLs and SME’s opinion working in Chronic Inducible Urticaria domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We have performed the competitive and market Intelligence analysis of the Chronic Inducible Urticaria Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Which geography accounted for the largest Chronic Inducible Urticaria market size?
The United States accounted for the largest Chronic Inducible Urticaria market size.
What is forecasted Chronic Inducible Urticaria size in 2030?
DelveInsight estimates an increase in Chronic Inducible Urticaria Market Size during the study period, 2017–2030
What are the present Chronic Inducible Urticaria drivers?
Need for curative therapy, Increasing awareness, the Rising prevalence are Chronic Inducible Urticaria drivers.
What are the Chronic Inducible Urticaria market barriers?
Need for biomarkers, Complex pathophysiology, Patient adherence, Need for CIndU specific population studies are the Chronic Inducible Urticaria market barriers.
How many companies are developing drugs for Chronic Inducible Urticaria?
Currently, only one key pharma player is developing the drug for CIndU.
Which are the leading companies in Chronic Inducible Urticaria market?
Key Player – Allakos Inc.
How is epidemiology segmented for Chronic Inducible Urticaria?
Chronic Inducible Urticaria epidemiology is segmented as Diagnosed prevalent cases of CU, Diagnosed prevalent cases of CIndU, Prevalence of chronic inducible urticaria by types
1 Key Insights
2 Executive Summary of Chronic Inducible Urticaria
3 SWOT Analysis for Chronic Inducible Urticaria
4 Chronic Inducible Urticaria Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017
4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030
5 Chronic Inducible Urticaria Market Overview at a Glance
5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017
5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030
6 Disease Background and Overview
6.1 Introduction
6.2 Types
6.3 Pathophysiology
6.4 Clinical features
6.5 Diagnosis
6.6 Clinical manifestation
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Total Prevalent Population of CIndU in 7MM
7.3 Assumptions and Rationale: 7MM
8 Country Wise-Epidemiology of Chronic Inducible Urticaria
8.1 The United States
8.1.1 Diagnosed Prevalent cases of CU in the United States
8.1.2 Diagnosed Prevalent cases of CIndU in the United States
8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States
8.2 EU5
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 Spain
8.2.5 The United Kingdom
8.3 Japan
8.3.1 Diagnosed Prevalent cases of CU in Japan
8.3.2 Diagnosed Prevalent cases of CIndU in Japan
8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan
9 Treatment and Management
9.1 Guidelines
10 Case Study
10.1 Severe cold urticaria including anaphylaxis
10.2 Severe symptomatic dermographism (urticaria factitia)
11 Patient Journey
12 Unmet Needs
13 Emerging Therapies
13.1 AK002: Allakos Inc.
13.1.1 Product Description
13.1.2 Clinical Development
13.1.3 Safety and Efficacy
14 Other Promising Therapies
14.1 CDX-0159: Celldex Therapeutics
14.1.1 Product Description
14.1.2 Clinical Development
14.1.3 Safety and Efficacy
15 Chronic Inducible Urticaria: Seven Major Market Analysis
15.1 Key Findings
15.2 Market Size of Chronic Inducible Urticaria (CIndU) in 7MM
16 Market Outlook by Country
16.1 Assumption and Rationale
16.2 United States
16.2.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.2.2 Chronic Inducible Urticaria Market Size by Therapies
16.3 Germany
16.3.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.3.2 Chronic Inducible Urticaria Market Size by Therapies
16.4 France
16.4.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.4.2 Chronic Inducible Urticaria Market Size by Therapies
16.5 Italy
16.5.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.5.2 Chronic Inducible Urticaria Market Size by Therapies
16.6 Spain
16.6.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.6.2 Chronic Inducible Urticaria Market Size by Therapies
16.7 UK
16.7.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.7.2 Chronic Inducible Urticaria Market Size by Therapies
16.8 Japan
16.8.1 Total Market size of Chronic Inducible Urticaria (CIndU)
16.8.2 Chronic Inducible Urticaria Market Size by Therapies
17 Market Drivers
18 Market Barriers
19 Appendix
19.1 Report Methodology
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
List of Table
Table 1: Summary of CIndU Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)
Table 3: Diagnosed Prevalent cases of CU in the United States (2017–2030)
Table 4: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)
Table 5: Prevalence of Chronic Inducible Urticaria by Types in the United States (2017–2030)
Table 6: Diagnosed Prevalent cases of CU in Germany (2017–2030)
Table 7: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)
Table 8: Prevalence of Chronic Inducible Urticaria by Types in Germany (2017–2030)
Table 9: Diagnosed Prevalent cases of CU in France (2017–2030)
Table 10: Diagnosed Prevalent cases of CIndU in France (2017–2030)
Table 11: Prevalence of Chronic Inducible Urticaria by Types in France (2017–2030)
Table 12: Diagnosed Prevalent cases of CU in Italy (2017–2030)
Table 13: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)
Table 14: Prevalence of Chronic Inducible Urticaria by Types in Italy (2017–2030)
Table 15: Diagnosed Prevalent cases of CU in Spain (2017–2030)
Table 16: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)
Table 17: Prevalence of Chronic Inducible Urticaria by Types in Spain (2017–2030)
Table 18: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)
Table 19: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)
Table 20: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom (2017–2030)
Table 21: Diagnosed Prevalent cases of CU in Japan (2017–2030)
Table 22: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)
Table 23: Prevalence of Chronic Inducible Urticaria by Types in Japan (2017–2030)
Table 24: Comparison of recommendations for confirming the relevance and threshold of triggers for inducible chronic urticaria (CU) in the EAACI/GA2LEN/EDF/WAO international guidelines and the US practice parameters for the diagnosis and management of CU
Table 25: AK002, Clinical Trial Description, 2020
Table 26: AK002, Clinical Trial Description, 2020
Table 27: Seven Major Market Size of CIndU in USD Million (2017–2030)
Table 28: The US Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 29: The US market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 30: Germany Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 31: Germany market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 32: France Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 33: France market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 34: Italy Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 35: Italy market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 36: Spain Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 37: Spain market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 38: UK Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 39: UK market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
Table 40: Japan Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Table 41: Japan market size of Chronic Inducible Urticaria by Therapies in USD Million (2017–2030)
List of Figures
Figure 1: SWOT Analysis
Figure 2: The Inflammation of Mast Cells in Chronic Inducible Urticaria
Figure 3: The Inflammation of Mast Cells in Chronic Inducible Urticaria
Figure 4: Recommended diagnostic algorithm for chronic urticaria
Figure 5: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)
Figure 6: Diagnosed Prevalent cases of CU in the United States (2017–2030)
Figure 7: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)
Figure 8: Prevalence of Chronic Inducible Urticaria by Types in the United States(2017–2030)
Figure 9: Diagnosed Prevalent cases of CU in Germany (2017–2030)
Figure 10: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)
Figure 11: Prevalence of Chronic Inducible Urticaria by Types in Germany(2017–2030)
Figure 12: Diagnosed Prevalent cases of CU in France (2017–2030)
Figure 13: Diagnosed Prevalent cases of CIndU in France (2017–2030)
Figure 14: Prevalence of Chronic Inducible Urticaria by Types in France(2017–2030)
Figure 15: Diagnosed Prevalent cases of CU in Italy (2017–2030)
Figure 16: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)
Figure 17: Prevalence of Chronic Inducible Urticaria by Types in Italy(2017–2030)
Figure 18: Diagnosed Prevalent cases of CU in Spain (2017–2030)
Figure 19: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)
Figure 20: Prevalence of Chronic Inducible Urticaria by Types in Spain(2017–2030)
Figure 21: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)
Figure 22: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)
Figure 23: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom(2017–2030)
Figure 24: Diagnosed Prevalent cases of CU in Japan (2017–2030)
Figure 25: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)
Figure 26: Prevalence of Chronic Inducible Urticaria by Types in Japan(2017–2030)
Figure 27: Recommended treatment algorithm for Chronic Urticaria
Figure 28: Patient journey Chronic Inducible Urticaria
Figure 29: Unmet Needs
Figure 30: 7 Major Market Size of Chronic Inducible Urticaria in USD Million (2017–2030)
Figure 31: Market Size of Chronic Inducible Urticaria in the United States, USD Millions (2017–2030)
Figure 32: The USS market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 33: Market Size of Chronic Inducible Urticaria in the Germany, USD Millions (2017–2030)
Figure 34: Germany market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 35: Market Size of Chronic Inducible Urticaria in the France, USD Millions (2017–2030)
Figure 36: France market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 37: Market Size of Chronic Inducible Urticaria in the Italy, USD Millions (2017–2030)
Figure 38: Italy market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 39: Market Size of Chronic Inducible Urticaria in the Spain, USD Millions (2017–2030)
Figure 40: Spain market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 41: Market Size of Chronic Inducible Urticaria in UK, USD Millions (2017–2030)
Figure 42: UK market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 43: Market Size of Chronic Inducible Urticaria in Japan, USD Millions (2017–2030)
Figure 44: Japan market size of Chronic Inducible Urticaria by therapies in USD Million (2017–2030)
Figure 45:Market Drivers
Figure 46: Market barriers
Allakos Inc.
Celldex Therapeutics
